Procedural and clinical impact of intravascular lithotripsy for the treatment of peri-stent calcification.

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- van Oort, Martijn J H
- Al Amri, Ibtihal
- Bingen, Brian O.
- -Soriano, Juan G. Cordoba
- Karalis, Ioannis
- Oliveri, Federico
- van der Kley, Frank
- Jukema, J. Wouter
- Jurado-Roman, Alfonso
- Montero-Cabezas, Jose M.
Grupos
Abstract
BACKGROUND: Use of intravascular lithotripsy (IVL) for treating peri-stent calcification is increasing. However, this indication remains 'off-label'. We aimed to investigate the efficacy and clinical outcomes of in-stent IVL. METHODS: Patients from five European centers who underwent in-stent IVL were included between 2019 and 2023. Demographic, clinical, procedural and follow-up data were collected from electronic hospital records. Angiographic and intracoronary imaging (ICI) data were analyzed in a centralized core-laboratory. RESULTS: Of 101 patients (71.2±9.2years), 56(55%) received in-stent IVL for late stent failure (median 109days post-PCI) due to calcific neoatherosclerosis or extra-stent calcification(late-IVL), while 45(45%) underwent bail-out IVL due to stent infraexpasion (immediate-IVL). Both late-IVL and immediate-IVL significantly improved angiographic %diameter stenosis (73.7[59.6-89.8]% to 16.4 [10.4-26.9]%;p<0.0001 and 28.6[22.5-43.3]% to 14.1[10.3-29.4]%;p<0.0001, and minimum lumen area (MLA) (3.4±1.2 to 8.6±2.5mm2;p<0.002 and 5.4±1.9 to 7.3±1.9;p<0.0001).Device(98%) and procedural success(80%) were high. MACE rates in-hospital (2%), 30-days (3%),6-months(5%) and 1-year(7%) were low and comparable in both groups. Acute diameter gain was lower in immediate-IVL (2.1±0.7mm vs. 0.5±0.4mm;p<0.0001). This, however, was explained by significant differences in pre-IVL angiographic and ICI parameters (%diameter stenosis 73.7[59.6-89.8] vs. 28.6[22.5-43.3]%; p<0.0001 and MLA (3.4±1.2 vs 5.4±1.9mm2; p<0.0001), whereas post-IVL percentage diameter stenosis (16.4(10.4-26.9) vs. 14.1(10.3-29.4);p=0.914) and MLA (8.6±2.5vs. 7.4±1.9mm2;p=0.064) in late- and immediate-IVL were comparable. CONCLUSIONS: IVL in-stent due to peri-stent calcification is an effective strategy, both late and immediately after stent implantation. Overall, MACE rates at short- and mid-term were low and comparable in both groups, although clinical findings should be taken with caution.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1553-8389, 1878-0938
- Tipo:
- Article
- Páginas:
- 16-23
- PubMed:
- 37923647
- Factor de Impacto:
- 0,486 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
CARDIOVASCULAR REVASCULARIZATION MEDICINE ELSEVIER INC
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- Calcific coronary artery disease; In-stent; Lithotripsy
Proyectos y Estudios Clínicos
MECANISMOS DE ENFERMEDAD EN LA MIOCARDIOPATIA ARRITMOGENICA, MEJORAS EN SU DIAGNOSTICO Y BUSQUEDA DE DIANAS TERAPEUTICAS.
Investigador Principal: ESTHER ZORIO GRIMA
PI14/01477 . INSTITUTO DE SALUD CARLOS III . 2015
INCORPORACIÓN GRUPOS CIBER. DR. DOLZ
Investigador Principal: LUIS VICENTE MARTÍNEZ DOLZ
CB16/11/00261 . INSTITUTO DE SALUD CARLOS III . 2017
ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, BASADO EN EVENTOS, QUE COMPARA LA EFICACIA Y SEGURIDAD DE RIVAROXABAN CON PLACEBO EN LA REDUCCIÓN DEL RIESGO DE MUERTE, INFARTO DE MIOCARDIO O ICTUS, EN PACIENTES CON INSUFICIENCIA CARDIACA Y ENFERMEDAD ARTERIAL CORONARIA SIGNIFICATIVA TRAS UN EPISODIO DE INSUFICIENCIA CARDIACA DESCOMPENSADA.
Investigador Principal: LUIS ALMENAR BONET
RIVAROXHFA3001/BAY59-7939/16302 . 2013
EVALUACIÓN, EN PACIENTES CON PROCESOS MÉDICOS, DE RIVAROXABAN FRENTE A PLACEBO EN LA REDUCCIÓN DEL RIESGO DE TROMBOEMBOLISMO VENOSO DESPUÉS DEL ALTA HOSPITALARIA. (MARINER).
Investigador Principal: JOSÉ ANTONIO TODOLÍ PARRA
RIVAROXDVT3002/BAY59-7939/17261
Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria.
Investigador Principal: JOSÉ LUIS DÍEZ GIL
BA-SCAD . 2021
ASSESSING THE EFFECT OF DAPAGLIFOZIN ON PLAQUE PROGRESSION IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION DAPA-PLACA.
Investigador Principal: JORGE SANZ SÁNCHEZ
DAPA-PLACA . 2021
Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures. DOAC-NOSTOP.
Investigador Principal: JORGE SANZ SÁNCHEZ
DOAC-NOSTOP . 2021
COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events COMBINE-INTERVENE Trial.
Investigador Principal: JORGE SANZ SÁNCHEZ
9357 . 2023
Revascularización percutánea de una oclusión crónica en arteria coronaria responsable de infarto previo para reducir la recurrencia de arritmias ventriculares. IRACTO-VT TRIAL.
Investigador Principal: JOSÉ LUIS DÍEZ GIL
IRACTO-VT TRIAL . 2023
Tratamiento antiplaquetario único con ticagrelor frente a aspirina después del implante percutáneo de válvula aórtica: ensayo clínico aleatorizado multicéntrico. REAC TAVI 2.
Investigador Principal: JEAN PAUL VILCHEZ TSCHISCHKE
REAC-TAVI2 . 2023
Plan de investigación de seguimiento clínico poscomercialización (PMCF) para evaluar la seguridad y la efectividad clínica del stent coronario Supraflex Cruz TM en el tratamiento de la enfermedad coronaria multivaso.
Investigador Principal: JOSÉ LUIS DÍEZ GIL
rEpic05 – Multiflex . 2023
Resultados isquémicos y hemorrágicos tras la implantaicón del stent angiolite y una terapia antiplaquetaria dual abreviada. Un ensayo controlado aleatorizado, muticéntrico, factorial 2x2, de todos los participantes elegibles ("all-comers"): Angiodapt.
Investigador Principal: JOSÉ LUIS DÍEZ GIL
ANGIODAPT-01 . 2023
Globo con revestimiento de sirolimus frente a stent con liberación de fármaco en vasos coronarios nativos. TRANSFORM II.
Investigador Principal: JORGE SANZ SÁNCHEZ
ASX2376 . 2023
“Tratamiento de placas vulnerables funcionalmente no significativas en pacientes con infarto de miocardio con elevación del ST y enfermedad multivaso.
Investigador Principal: JEAN PAUL VILCHEZ TSCHISCHKE
Epic28 . 2023
Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with ST-segment elevation myocardial infarction.
Investigador Principal: JORGE SANZ SÁNCHEZ
COPERNICAN TRIAL . 2024
Cita
van MJH,Al Amri I,Bingen BO,JGC,Karalis I,SANZ J,Oliveri F,van der Kley F,Jukema JW,Jurado A,Montero JM. Procedural and clinical impact of intravascular lithotripsy for the treatment of peri-stent calcification. Cardiovasc. Revascularization Med. 2023. 61. p. 16-23.